TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29630023

Group type: EXPERIMENTAL
Intervention: Immediate insertion after D&E
Number of subjects: 120

Group type: COMPARATOR
Intervention: Delayed insertion (2-4 weeks post-D&E)
Number of subjects: 120
Study: 25756323

Group type: EXPERIMENTAL
Intervention: Incline treadmill running (INC) at 75%Vmax
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Incline treadmill running (INC) at 80%Vmax
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Incline treadmill running (INC) at 85%Vmax
Number of subjects: 12

Group type: COMPARATOR
Intervention: Level-grade running at Vmax
Number of subjects: 12
Study: 24442226

Group type: EXPERIMENTAL
Intervention: Pregnant period
Number of subjects: 2269

Group type: COMPARATOR
Intervention: Nonpregnant period
Number of subjects: 2269

Group type: COMPARATOR
Intervention: Postpartum period
Number of subjects: 2269
Study: 23012594

Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: NSAID-only users
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: NSAID use
Number of subjects: 168
Study: 19567893

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 795

Group type: COMPARATOR
Intervention: Nortriptyline
Number of subjects: 795
Study: 17519080

Group type: EXPERIMENTAL
Intervention: Vildagliptin 100 mg once daily
Number of subjects: 16
Study: 15464786

Group type: EXPERIMENTAL
Intervention: Vitamin C (1000 mg) and Vitamin E (400 IU)
Number of subjects: 756

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 756
Study: 11488788

Group type: EXPERIMENTAL
Intervention: Stapled haemorrhoidectomy
Number of subjects: 200

Group type: COMPARATOR
Intervention: Milligan-Morgan haemorrhoidectomy
Number of subjects: 200
Study: 7993133

Group type: EXPERIMENTAL
Intervention: Behavior management program
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Social skills program
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 33
Study: 3180198

Group type: EXPERIMENTAL
Intervention: Flunarizine
Number of subjects: 521

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 521
Study: 31937352

Group type: EXPERIMENTAL
Intervention: 2 g/day krill oil
Number of subjects: 260

Group type: COMPARATOR
Intervention: Inert placebo
Number of subjects: 260
Study: 31699720

Group type: EXPERIMENTAL
Intervention: Foley catheter balloon (FCB)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Prostaglandin E2 (PGE2)
Number of subjects: 100
Study: 28319122

Group type: EXPERIMENTAL
Intervention: PRONTO training (simulation and team-training program)
Number of subjects: 641
Study: 26123096

Group type: EXPERIMENTAL
Intervention: Atrial fibrillation patients (AF)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Atrial fibrillation patients (AF) during AV pacing
Number of subjects: 27

Group type: COMPARATOR
Intervention: Controls during AV pacing
Number of subjects: 27
Study: 22970738

Group type: EXPERIMENTAL
Intervention: Indomethacin 0.1% eye drops
Number of subjects: 86

Group type: COMPARATOR
Intervention: Ketorolac 0.5% eye drops
Number of subjects: 86
Study: 21534021

Group type: EXPERIMENTAL
Intervention: Risk-adapted dental care (RaDC)
Number of subjects: 800

Group type: COMPARATOR
Intervention: Conventional dental care
Number of subjects: 800
Study: 19927141

Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-amount/moderate-intensity exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-amount/vigorous-intensity exercise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Regular walking exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Inactive individuals
Number of subjects: 0
Study: 16500491

Group type: EXPERIMENTAL
Intervention: ivMCE (intravenous myocardial contrast echocardiography)
Number of subjects: 16
Study: 12404073

Group type: EXPERIMENTAL
Intervention: Heroin (491 mg average daily dose, n=17)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Morphine (597 mg average daily dose, n=16)
Number of subjects: 33
Study: 10846637

Group type: EXPERIMENTAL
Intervention: Selected yoga practices (1 hr/session, morning and evening for 11 weeks)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Medical treatment (drug intake every day for the whole experimental period)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 33
Study: 9160923

Group type: EXPERIMENTAL
Intervention: ranitidine 300 mg twice daily for 2 weeks
Number of subjects: 117

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 117
Study: 8198040

Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise (70% of heart rate reserve)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: High-intensity exercise (80% to 85% of heart rate reserve)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 44
Study: 2836189

Group type: EXPERIMENTAL
Intervention: Low-fat diet (more carbohydrate)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Medium-fat diet (more sunflower oil)
Number of subjects: 6
Study: 29704228

Group type: EXPERIMENTAL
Intervention: SG + TB
Number of subjects: 20

Group type: COMPARATOR
Intervention: SMT
Number of subjects: 20
Study: 26011772

Group type: EXPERIMENTAL
Intervention: Real acupuncture
Number of subjects: 15

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 15
Study: 26174114

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (FF) and umeclidinium (UMEC) 100/250 mcg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Umeclidinium (UMEC) as monotherapy
Number of subjects: 0
Study: 24358760

Group type: EXPERIMENTAL
Intervention: Improved central venous catheter indwelling of intraperitoneal drainage, irrigation, cavity injection, combined with systemic comprehensive treatment
Number of subjects: 54

Group type: COMPARATOR
Intervention: Routine paracentesis
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Improved central venous catheter indwelling
Number of subjects: 54
Study: 21923249

Group type: EXPERIMENTAL
Intervention: Peg‐IFN‐α 2b + RBV + ALC
Number of subjects: 60

Group type: COMPARATOR
Intervention: Peg‐IFN‐α 2b + RBV
Number of subjects: 60
Study: 18454096

Group type: EXPERIMENTAL
Intervention: Selank (30 patients)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Medazepam (32 patients)
Number of subjects: 62
Study: 16816661

Group type: EXPERIMENTAL
Intervention: Reduction mammaplasty (surgery within 6 weeks)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control group (surgery 6 months after recruitment)
Number of subjects: 73
Study: 15018686

Group type: EXPERIMENTAL
Intervention: Evaluating current relationships against a romantic stereotype (Study 1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Evaluating alternative relationships against a high standard (Studies 2 and 3)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Evaluating alternative relationships against a low standard (Studies 2 and 3)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perceived quality of alternatives
Number of subjects: 0
Study: 11012133

Group type: EXPERIMENTAL
Intervention: Fetal pulse oximetry
Number of subjects: 0

Group type: COMPARATOR
Intervention: Electronic fetal heart rate monitoring
Number of subjects: 0
Study: 9108978

Group type: EXPERIMENTAL
Intervention: Group II (Vasurfilcon A) contact lenses
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Group IV (Vifilcon A) contact lenses
Number of subjects: 20
Study: 8498602

Group type: EXPERIMENTAL
Intervention: Low energy availability (8 kcal.kg body wt‐1.day‐1)
Number of subjects: 46

Group type: COMPARATOR
Intervention: High energy availability (30 kcal.kg body wt‐1.day‐1)
Number of subjects: 46
Study: 3104494

Group type: EXPERIMENTAL
Intervention: Suprofen 200 mg
Number of subjects: 59

Group type: COMPARATOR
Intervention: Paracetamol 500 mg
Number of subjects: 59
Study: 28632643

Group type: EXPERIMENTAL
Intervention: Brace group
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 43
Study: 28038680

Group type: EXPERIMENTAL
Intervention: Mycophenolate (MMF) for 2 years
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Oral cyclophosphamide (CYC) for 1 year followed by 1 year of placebo
Number of subjects: 142

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 142
Study: 24998644

Group type: EXPERIMENTAL
Intervention: Vaccine-induced inflammation (typhoid vaccination)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (non-inflamed condition)
Number of subjects: 18
Study: 22704742

Group type: EXPERIMENTAL
Intervention: Internet support with a website for goal-setting and self-monitoring of weight and exercise plus minimal personal support
Number of subjects: 330

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 330
Study: 20526887

Group type: EXPERIMENTAL
Intervention: 9-cm pillow
Number of subjects: 50

Group type: COMPARATOR
Intervention: No pillow
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 3-cm or 6-cm pillow
Number of subjects: 50
Study: 19256282

Group type: EXPERIMENTAL
Intervention: Low-fat, low-energy, lacto-ovo-vegetarian diet and exercise in a stress-free environment for one week
Number of subjects: 1349
Study: 16183441

Group type: EXPERIMENTAL
Intervention: Nesiritide
Number of subjects: 237

Group type: COMPARATOR
Intervention: Standard Care (SCP)
Number of subjects: 237
Study: 12794401

Group type: EXPERIMENTAL
Intervention: Dopamine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Norepinephrine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Epinephrine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Epinephrine (severe shock)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Norepinephrine (severe shock)
Number of subjects: 20
Study: 11061767

Group type: EXPERIMENTAL
Intervention: Clinical pathway for inpatient asthma management
Number of subjects: 110

Group type: COMPARATOR
Intervention: Conventional ward (control group)
Number of subjects: 110
Study: 8840384

Group type: EXPERIMENTAL
Intervention: Nutritional supplements
Number of subjects: 3939

Group type: EXPERIMENTAL
Intervention: Single-ingredient supplements
Number of subjects: 3939

Group type: EXPERIMENTAL
Intervention: Demographic factors and access to health care
Number of subjects: 3939
Study: 1621440

Group type: EXPERIMENTAL
Intervention: Horse chestnut seed extract
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 3912960

Group type: EXPERIMENTAL
Intervention: Omeprazole 30 mg/day
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Omeprazole 10 mg/day
Number of subjects: 12
Study: 29847529

Group type: EXPERIMENTAL
Intervention: Battle Rope (BR) Training
Number of subjects: 30

Group type: COMPARATOR
Intervention: Shuttle Run (SR) Training
Number of subjects: 30
Study: 26350260

Group type: EXPERIMENTAL
Intervention: Subvastus approach (SVA)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Medial parapatellar approach (MPA)
Number of subjects: 50
Study: 24811237

Group type: EXPERIMENTAL
Intervention: Early Developmental Intervention (EDI)
Number of subjects: 376

Group type: COMPARATOR
Intervention: Health Education Intervention (Control)
Number of subjects: 376
Study: 22031508

Group type: EXPERIMENTAL
Intervention: 100% long-chain triacylglycerols (LCT) emulsion
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 50/50% medium-chain triacylglycerols (MCT)/LCT emulsion
Number of subjects: 9

Group type: COMPARATOR
Intervention: Glycerol
Number of subjects: 9
Study: 20530096

Group type: COMPARATOR
Intervention: Non-penetrating control needle
Number of subjects: 10

Group type: COMPARATOR
Intervention: Skin-touch placebo needle
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Penetrating needle
Number of subjects: 10
Study: 18237683

Group type: EXPERIMENTAL
Intervention: Impaired myocardial perfusion (TMPG 0/1/2)
Number of subjects: 3491

Group type: EXPERIMENTAL
Intervention: Restoration of normal epicardial flow (Thrombolysis In Myocardial Infarction flow grade 3) with impaired TMPG
Number of subjects: 3491

Group type: EXPERIMENTAL
Intervention: Patients with left ventricular ejection fraction >or=30% and impaired TMPG
Number of subjects: 3491

Group type: EXPERIMENTAL
Intervention: VT/VF occurrence
Number of subjects: 3491

Group type: EXPERIMENTAL
Intervention: Patients with VT/VF and impaired TMPG
Number of subjects: 3491
Study: 15955629

Group type: EXPERIMENTAL
Intervention: G2019S mutation testing in Parkinson's disease patients
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 1000
Study: 12702130

Group type: EXPERIMENTAL
Intervention: HIV‐1 rgp160 vaccine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Tetanus vaccine
Number of subjects: 30

Group type: COMPARATOR
Intervention: No immunization
Number of subjects: 30

Group type: COMPARATOR
Intervention: Tetanus vaccine (Control group)
Number of subjects: 30
Study: 10233027

Group type: EXPERIMENTAL
Intervention: Estradiol-17beta (1 mg micronized steroid twice daily orally)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 7546802

Group type: EXPERIMENTAL
Intervention: Group I: Two or three cycles of cisplatin, vinblastine and mitomycin C
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Group II: Two cycles of cisplatin, VP16, alpha 1 timosine and interferon
Number of subjects: 110
Study: 2007152

Group type: EXPERIMENTAL
Intervention: Peer-led education program
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Adult-led education program
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Satisfaction with providers
Number of subjects: 82
Study: 6974543

Group type: EXPERIMENTAL
Intervention: Distal splenorenal shunt
Number of subjects: 42

Group type: COMPARATOR
Intervention: Central splenorenal shunt
Number of subjects: 42
Study: 30737048

Group type: EXPERIMENTAL
Intervention: School-based nutrition and physical activity intervention using IVAC methodology
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 28024819

Group type: EXPERIMENTAL
Intervention: Lava C.O.S. CAD software and centralized CAM (group L)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cares CAD software and centralized CAM (group iT)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cerec Connect CAD software and lab side CAM (group CiL)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cerec Connect CAD software with centralized CAM (group CiD)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Conventional fabrication (group K)
Number of subjects: 10
Study: 26538305

Group type: EXPERIMENTAL
Intervention: 4 h sleep/night for five nights followed by one night with 12 h recovery sleep (experimental group)
Number of subjects: 47

Group type: COMPARATOR
Intervention: 10 h sleep/night (control group)
Number of subjects: 47
Study: 24308946

Group type: EXPERIMENTAL
Intervention: Prophylaxis maintained for 12 months
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Prophylaxis maintained for 24 months
Number of subjects: 50
Study: 23048053

Group type: EXPERIMENTAL
Intervention: Mentored training on a virtual reality simulator
Number of subjects: 27

Group type: COMPARATOR
Intervention: No simulator training (control)
Number of subjects: 27
Study: 19542207

Group type: EXPERIMENTAL
Intervention: Anakinra (recombinant human IL-1Ra) for 13 weeks
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 17295575

Group type: EXPERIMENTAL
Intervention: Curriculum plus teacher consultation (Level A)
Number of subjects: 1484

Group type: EXPERIMENTAL
Intervention: Level A plus small-group training (Level B)
Number of subjects: 1484

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 1484
Study: 15368794

Group type: EXPERIMENTAL
Intervention: Radiofrequency fistulectomy (Group A)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional fistulotomy (Group B)
Number of subjects: 20
Study: 12229073

Group type: EXPERIMENTAL
Intervention: Tracking procedures used in Project Towards No Drug Abuse (Project TND)
Number of subjects: 0
Study: 9640572

Group type: EXPERIMENTAL
Intervention: 0.3% gentamicin sulfate eyedrops
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 8090461

Group type: EXPERIMENTAL
Intervention: Original strict criteria for progression based on duplicate testing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Revised criteria for progression with raised requirement for deterioration and repeated duplicate testing
Number of subjects: 0
Study: 2768706

Group type: EXPERIMENTAL
Intervention: Cholestyramine
Number of subjects: 3806

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3806

Group type: EXPERIMENTAL
Intervention: Positive test (combined groups)
Number of subjects: 3806

Group type: EXPERIMENTAL
Intervention: Positive test
Number of subjects: 3806
Study: 71995

Group type: EXPERIMENTAL
Intervention: Tadenan
Number of subjects: 20
Study: 31238912

Group type: EXPERIMENTAL
Intervention: Reduced-dosage ketoprofen (0.5 mg/kg SC once; 0.25 mg/kg PO daily)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Reduced-dosage ketoprofen (0.5 mg/kg SC once; 0.25 mg/kg PO daily) + tramadol (5 mg/kg/day PO)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard-dosage ketoprofen (2 mg/kg SC, then 1 mg/kg PO daily)
Number of subjects: 20
Study: 29027511

Group type: EXPERIMENTAL
Intervention: Fcomp on
Number of subjects: 10

Group type: COMPARATOR
Intervention: Fcomp off
Number of subjects: 10
Study: 26355973

Group type: EXPERIMENTAL
Intervention: ASO (anterior subapical osteotomy of the mandible)
Number of subjects: 32

Group type: COMPARATOR
Intervention: BPsO (bilateral parasymphyseal osteotomy of the mandible)
Number of subjects: 32
Study: 23403860

Group type: EXPERIMENTAL
Intervention: Respondent-driven sampling (RDS)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Conventional outreach-based HTC
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Flat incentive ($20)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Conditional incentive ($10-35)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Both incentive groups
Number of subjects: 48
Study: 21606427

Group type: COMPARATOR
Intervention: Fluorouracil (225 mg/m(2)/d) plus pelvic radiation (50.4 Gy in 28 daily fractions)
Number of subjects: 747

Group type: EXPERIMENTAL
Intervention: Fluorouracil (225 mg/m(2)/d) plus pelvic radiation (50.4 Gy in 28 daily fractions) and oxaliplatin (60 mg/m(2) weekly × 6)
Number of subjects: 747
Study: 19138610

Group type: EXPERIMENTAL
Intervention: Superior joint space injections of sodium hyaluronate
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Inferior joint space injections of sodium hyaluronate
Number of subjects: 120
Study: 17443855

Group type: EXPERIMENTAL
Intervention: Shouldice repair
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Lichtenstein repair
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: TAPP repair
Number of subjects: 280

Group type: COMPARATOR
Intervention: Tension-free repairs
Number of subjects: 280
Study: 15582012

Group type: EXPERIMENTAL
Intervention: 75 mg of dried ethanolic extract of guarana (approx 12% caffeine)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 200 mg of Panax ginseng (G115)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Combination of 75 mg guarana and 200 mg Panax ginseng
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 11328420

Group type: EXPERIMENTAL
Intervention: Postoperative intravesical instillation of mitomycin C (20 mg) and cytosine arabinoside (200 mg) 28 times over 2 years
Number of subjects: 25

Group type: COMPARATOR
Intervention: Non-instillation group
Number of subjects: 25
Study: 9849314

Group type: EXPERIMENTAL
Intervention: Allopurinol 300 mg/day
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Benzbromarone 100 mg/day
Number of subjects: 86

Group type: COMPARATOR
Intervention: Allopurinol 450 to 600 mg/day
Number of subjects: 86

Group type: COMPARATOR
Intervention: Benzbromarone (mean final dose 76 mg/day)
Number of subjects: 86
Study: 7986969

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg b.d.
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg b.d.
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg q.d.s.
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Ranitidine 600 mg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Ranitidine 1200 mg
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 2722308

Group type: EXPERIMENTAL
Intervention: 3 x 450 mg 3‐sn‐polyenyl‐phosphatidylcholine (PPC)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 30272856

Group type: EXPERIMENTAL
Intervention: Standard meal with exercise
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 20% protein meal with exercise
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 50% protein meal with exercise
Number of subjects: 9

Group type: COMPARATOR
Intervention: Standard meal
Number of subjects: 9

Group type: COMPARATOR
Intervention: 20% protein meal
Number of subjects: 9

Group type: COMPARATOR
Intervention: 50% protein meal
Number of subjects: 9
Study: 27096358

Group type: EXPERIMENTAL
Intervention: Continuing therapeutic CPAP
Number of subjects: 45

Group type: COMPARATOR
Intervention: Subtherapeutic CPAP (CPAP withdrawal)
Number of subjects: 45
Study: 25332469

Group type: EXPERIMENTAL
Intervention: Calcium (100 mg/test meal)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Calcium (200 mg/test meal)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ascorbic acid (AA) at 42.5 mg/test meal
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ascorbic acid (AA) at 85 mg/test meal
Number of subjects: 30
Study: 23895132

Group type: EXPERIMENTAL
Intervention: Kaempferol (150 mg/kg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Kaempferol (30 mg/kg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Fenofibrate (12 mg/kg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Model group (high cholesterol diet)
Number of subjects: 30
Study: 20607216

Group type: EXPERIMENTAL
Intervention: Pubovaginal sling (PVS)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Tension-free vaginal tape (TVT)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Both PVS and TVT
Number of subjects: 63
Study: 18166838

Group type: EXPERIMENTAL
Intervention: Pemetrexed (500 mg/m2 once every 3 weeks)
Number of subjects: 488

Group type: COMPARATOR
Intervention: Docetaxel (75 mg/m2 once every 3 weeks)
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: Pemetrexed and Docetaxel (pooled data)
Number of subjects: 488